Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.

Related Articles

Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer.

Endocr Relat Cancer. 2019 Jun 01;:

Authors: Lin SF, Lin JD, Yeh CN, Huang YT, Chou TC, Wong RJ

Polo-like kinases (PLKs) are pivotal regulators of cell proliferation and cell survival; therefore, PLKs may be potential targets in the treatment of malignancy. The therapeutic effects of volasertib, a PLKs inhibitor for papillary and follicular thyroid cancer (known as well-differentiated thyroid cancer) were evaluated in this study. Volasertib inhibited cell proliferation in two papillary and two follicular thyroid cancer cell lines in a dose-dependent manner. Volasertib treatment reduced cells in S phase and increased cells in G2/M phase. Volasertib activated caspase-3 activity and induced apoptosis. Drug combinations of volasertib and sorafenib showed mostly synergism in four well-differentiated thyroid carcinoma cell lines in vitro. Volasertib treatment in vivo retarded the growth of a papillary thyroid tumor model. Furthermore, the combination of volasertib with sorafenib was more effective than either single treatment in a follicular thyroid cancer xenograft model. Promising safety profiles appeared in animals treated with either volasertib alone or volasertib and sorafenib combination therapy. These findings support volasertib as a potential drug for the treatment of patients with well-differentiated thyroid cancer.

PMID: 31189135 [PubMed – as supplied by publisher]

Source link

Related posts

Using Botox Preventively – Does it Work?


Get Rid of Fat With CoolSculpting®


Why it’s important for Cosmetic Surgeons and Physicans to be affiliated with CPCA


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy